Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster viewing and lunch

136P - Clinical Implications of Non-Breast Cancer Related Findings in Breast Cancer Patients Undergoing PET/CT scan prior to Neoadjuvant Systemic Therapy

Date

12 May 2023

Session

Poster viewing and lunch

Presenters

Josefien van Olmen

Citation

Annals of Oncology (2023) 8 (1suppl_4): 101220-101220. 10.1016/esmoop/esmoop101220

Authors

J. van Olmen1, M. Schrijver2, F.H. van Duijnhoven1, C.E. Loo2, M. Stokkel2, I. van der Ploeg2

Author affiliations

  • 1 Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam/NL
  • 2 NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam/NL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 136P

Background

Breast cancer patients undergoing PET/CT scans for neoadjuvant systemic therapy may have non-breast cancer (BC) related finding. The aim of this study is to describe the incidence, additional work-up and possible impact of these findings.

Methods

We included BC patients who underwent a PET/CT scan in our institute between 2011-2019 prior to neoadjuvant systemic therapy. An additional finding was defined as a non-physiologic abnormal lesion only depicted by PET/CT. Patients with a BC-related or no additional finding were excluded. For the remaining patients with a non-BC related additional finding, we retrospectively gathered information on the additional work-up and the clinical consequences.

Results

Of the 1337 patients included, 561 had additional findings on PET-CT, of whom 258 had a non-BC related additional finding. Further work-up was conducted in 202 patients (78%), including 282 examinations during initial work-up. In these 202 patients the non-BC related findings were detected in the endocrine region (26%), gastro-intestinal region (16%), lungs (15%), bones (14%), distant lymph nodes (11%), urogenital region (11%), liver (10%) and other (5%). In the end, 17 (8%) of the 202 patients were diagnosed with malignant and 138 patients (68%) with benign lesions. Only 8 patients (4%) had an additional non-BC related finding that was considered a more prognosis-determining diagnosis than their breast cancer disease. Malignant and prognosis-determining non-BC related additional findings mostly occurred in the endocrine, gastro-intestinal and urogenital region.

Conclusions

PET/CT scans used for dissemination imaging in breast cancer patients detect a high number of non-BC related additional findings, with the majority being clinically irrelevant and causing a relatively large amount of unnecessary additional work-up. Additional non-BC related findings in the endocrine, gastro-intestinal and urogenital region have a higher change of being malignant. Clinicians should be aware of potential non-BC related PET/CT findings and carefully consider the clinical implications.

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.